Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Cilnidipine is a potent, long-acting dihydropyridine calcium channel blocker primarily utilized in the management of hypertension. Its chemical identity is defined by the molecular formula C28H35NO6 and it is registered under the CAS number 97104-15-9. Structurally, Cilnidipine distinguishes itself from many other antihypertensive agents through its unique dual mechanism of action. While it acts as a selective antagonist on L-type calcium channels found in vascular smooth muscle cells to induce vasodilation, it simultaneously inhibits N-type calcium channels located in sympathetic nerve terminals. This dual blockade effectively reduces peripheral vascular resistance while also attenuating sympathetic nervous system overactivity, which often contributes to elevated blood pressure and target organ damage.
Clinically, Cilnidipine is widely prescribed for essential hypertension, offering significant benefits beyond simple blood pressure reduction. By suppressing norepinephrine release via N-type channel inhibition, it helps protect against renal damage, a common complication in hypertensive patients. Studies suggest that this drug may reduce proteinuria and preserve renal function more effectively than pure L-type blockers like amlodipine or nifedipine. Furthermore, its long half-life allows for once-daily dosing, ensuring stable plasma concentrations and minimizing peak-trough fluctuations that can lead to reflex tachycardia or edema.
The therapeutic profile of Cilnidipine makes it particularly valuable for patients with high sympathetic tone, those suffering from diabetic nephropathy, or individuals requiring robust blood pressure control without severe cardiovascular side effects. It is generally well-tolerated, though common adverse events may include mild ankle edema, flushing, or headache. As a second-generation calcium channel blocker, Cilnidipine represents an advanced pharmacological approach to treating cardiovascular disease, balancing efficacy with organ protection. Its development highlights the ongoing evolution of antihypertensive therapy towards more targeted mechanisms that address both hemodynamic parameters and neurohormonal pathways, ultimately aiming to improve long-term patient outcomes and quality of life in chronic disease management.